Search
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn.
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.
Estetrol
go.drugbank.com/drugs/DB12235ApprovedInvestigational[L33184] On April 15 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals were granted FDA approval for the oral contraceptive Estelle/Nextstellis, a combination of [drospirenone] and estetrol
Pegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]
Acarbose
go.drugbank.com/drugs/DB00284ApprovedInvestigational[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada.
Idecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigational[A232955, A232960] In September 2023, the FDA also approved cipaglucosidase alfa for similar indications.[L49241]